Translational Scientist

€90k - €120k

Location
Berlin
Workplace
Hybrid
Employment
Full-time

About this role

Your mission

  • End-to-end ownership of key clinical projects, from defining the clinical question, to data collection and cleaning, to publications as lead author.
  • Generate clinically meaningful insights that support clinical adoption, regulatory submissions, reimbursement and guideline inclusion.
  • Present findings at international conferences, and represent StratifAI in discussions with clinical and research partners.
  • Identify evidence gaps and design studies to address them. Develop research questions, protocols and analysis plans together with an interdisciplinary team.
  • Support existing scientific collaborations, identify new opportunities and prepare research proposals and applications for access to real-world and clinical-trial data.

Your profile

  • A PhD, MD or equivalent qualification in computational biology, biomedical engineering, oncology, cancer biology or a related discipline, with a deep understanding of medical statistics.
  • Demonstrated expertise in cancer biology, and an understanding of clinical guidelines on how existing biomarkers inform treatment decisions.
  • Experience designing and executing statistical analysis protocols for clinical studies involving biomarkers, ideally in computational pathology.
  • Strong Python skills and a core understanding of deep learning.
  • A track record of first or last authored peer-reviewed publications and presentations at oncology journals/conferences.

Why us?

  • The opportunity to build the evidence for novel AI biomarkers that are used in the real world, that could make a meaningful difference to cancer patients.
  • Ownership of clinical projects from the initial question to publication and subsequent implications on product development.
  • Fully covered frequent travels to the major oncology conferences around the world.
  • Highly competitive salary.
  • Equity to share in the company's success.
  • Direct collaboration with the founders, an interdisciplinary team, and a scientific advisory board of world-class oncologists and key opinion leaders.
  • Office space in the heart of Berlin.

About us

StratifAI is an innovative precision oncology startup developing the next generation of multimodal AI-based cancer biomarkers, with offices in Berlin and New York. Our products are developed with data that is collected in routine patient care, such as histology slides, clinical variables, and longitudinal outcome data. This enables us to develop and provide our biomarkers at scale, allowing cancer patients globally to receive the right treatment at the right time. Our first product, Polaris™ Breast, assesses the risk of distant metastasis at 5- and 10-years for patients with early breast cancer and is expected to be available for clinical use in Q1 2027 on the US as laboratory-developed test.

Apply to StratifAI

Clera fills in StratifAI's application for you.

How it works

Open the role in Clera

Sign in, and this role opens on your Clera job board, ready to apply.

Clera fills in the application

Clera fills the form from your profile and resume, and asks what's missing.

Track it in Clera

Each application you send shows up in your Clera tracker, sorted by stage.

Want Clera to find roles for you?

Ask your AI about this role

It knows you. Clera gives it the role.

Does this role fit my profile?

First time? Connect Clera once, about a minute.
One click above pre-fills the connector. Or by hand: Settings > Connectors > Add custom connector, paste https://mcp.getclera.com. Either way, sign in with the account you use on Clera and approve the consent screen.
https://mcp.getclera.com

Sign in with your Clera account. MCP docs

About StratifAI

StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics. Our discovery platform, Polaris™, applies multimodal AI to clinical data, identifying prognostic and predictive biomarkers that enable more equitable and individualized treatment strategies across solid-tumor cancers.

Polaris™ Breast, the company’s first diagnostic, assesses metastatic risk in early breast cancer directly from digitized histology slides, supporting better treatment decisions. Retrospectively validated on thousands of patients from Phase III trials and real-world clinical settings, Polaris™ Breast is available for research use only and is undergoing regulatory approval in the EU and US.

Team size
11-50 employees people
Founded
2023
Industry
Hospitals and Health Care
Workplace
Hybrid
Locations
Berlin, Germany

Benefits

  • Competitive salary
  • Equity
  • Travel to international conferences
  • Interdisciplinary team collaboration